Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

t on Form 10-K for the year ended December 31, 2011 and Form 10-Q for the quarter ended September 30, 2012. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

 NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) Three Months EndedDecember 31, Year EndedDecember 31, 2012201120122011Revenues:Sponsored research and development

$
3,959

$
,873

$
8,897

$
,462Milestones and license fees

7,988

9,237

34,243

66,951Total revenues

21,947

11,110

53,140

77,413Operating expenses:Research and development

9,097

8,002

37,163

30,951General and administrative

3,311

2,668

13,437

12,458Cease-use expense

957

(7)

1,092

82Total operating expenses

13,365

10,663

51,692

43,491Income from operations

8,582

447

1,448

33,922Other income:Gain on sale/disposal of assets

7

58

32

242Deferred gain on real estate

766

744

3,042

2,953Investment income, net

130

77

489

418Other income, net

5

5

14

36Total other income

908

884

3,577

3,649Net income

$
9,490

$
,331

$
5,025

$
37,571Net income per common share:Basic

$
.14

$
.02

$
.08

$
.68Diluted

$
.14

$
.02

$
.08

$
.67Shares used in the calculation of net income per common share:Basic

66,406

55,259

65,619

55,176Diluted

67,720

56,461

66
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
(Date:12/17/2014)... 17, 2014 Xeno Diagnostics has ... its most recent COLA inspection. Xeno has met ... national healthcare accreditation organization. Accreditation is earned only ... in day-to-day operations, demonstrate continued accuracy in the ... on-site laboratory survey. , While the ...
(Date:12/17/2014)... Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... disease, today announced the next step in its expanded ... solutions provider with the naming of current Chief Operating ... Executive Officer, while current Chairman of the Board and ... as Chairman. These changes are effective January 1, 2015. ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... DENVER, Colorado and JERUSALEM, September 16 Children,s,Hospital ... today,that Children,s Hospital is enrolling patients for the ExCell ... cord blood transplant sites,worldwide, five of which are children,s ... Hungary and Israel. The trial is researching the,safety and ...
... , ... Highly Automated QT(sm) and QT Beat-to-Beat(sm) to Improve Precision and Reduce Risk of False ... Rochester, ... core lab services and QT analysis, announced today that a top 15 pharmaceutical company ...
... , , , ST. LOUIS, ... be presenting at the UBS Global Life Sciences Conference on Monday, ... NY. Interested parties may listen via live audio broadcast over the ... the "Webcast" icon to access this file. , , ...
Cached Biology Technology:Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... University researchers is examining a new vaccine method that ... Wannemuehler and his team of researchers is hoping to ... use smaller doses and require only one trip to ... been prepared from killed bacteria. The vaccinated person,s immune ...
... available in French . A ... McGill Universitys Department of Microbiology and Immunology has discovered ... regulate the bodys autoimmune reactions may lose their effectiveness ... of type 1 diabetes. The study conducted on ...
... 2008 The Rwandan government, Great Ape Trust of ... Reserve is the future site of the Rwanda National ... ambitious forest restoration and ecological research efforts ever. The ... national conservation park comes less than three months after ...
Cached Biology News:Iowa State researchers look for smaller, cheaper, 1-dose vaccines 2Type 1 diabetes triggered by 'lazy' regulatory T-cells: McGill researchers 2Rwanda's Gishwati Forest selected as site for historic conservation project 2Rwanda's Gishwati Forest selected as site for historic conservation project 3
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Black Polypropylene 384 Round Well Plate 70/Box...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: